Product/Composition:- | Sunitinib |
---|---|
Strength:- | 12.5 mg, 25 mg, 37.5 mg, 50 mg |
Form:- | Tablet |
Reference Brands:- | Sutent® (EU & US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Sunitinib Tablets are oral oncology drugs used for renal cell carcinoma and GIST treatment. Available in 12.5 mg to 50 mg strengths, compliant with EU-GMP and USFDA standards. Ideal for B2B supply, private labeling, and hospital tenders across regulated markets.
Sunitinib Tablets are oral tyrosine kinase inhibitors used to treat renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors. Available in 12.5 mg, 25 mg, 37.5 mg, and 50 mg film-coated tablets, our products comply with EU-GMP and USFDA standards. Offered for B2B supply, contract manufacturing, and private labeling, Sunitinib comes with full regulatory documentation including CTD dossiers and bioequivalence data. Trusted by distributors and hospital pharmacies across the US and EU, these tablets ensure consistent quality and efficacy for oncology treatment programs in regulated markets.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications